Articles related to PEDIATRIC ALLERGIES

The FDA expanded the indication for olopatadine hydrochloride and mometasone furoate nasal spray to include children aged 6 to younger than 12 years with seasonal allergic rhinitis. Approval was supported by a phase 3 trial demonstrating improved nasal symptoms versus placebo.

A retrospective study of 606 pediatric patients found serum specific IgE testing for allergic rhinitis was frequently negative in children younger than 3 years and became more informative with age. Findings may aid diagnostic decision-making, though prospective validation is needed.

The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.

“This device will become many patients’ primary epinephrine device because it removes the hurdle to administering epinephrine earlier in the anaphylactic process.” — Haley Overstreet, MD, Aspire Allergy & Sinus

“Today’s approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment.” – Iilun Murphy, MD, Director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research

The Sonu Band, now FDA-cleared for children 12+, showed a -2.74 mean TNSS improvement with no adverse events in a 2-week study.